NCT06439966 2026-02-12
Expanded Access to ABBV-787
AbbVie
No longer available
Clinical Trials
9 trialsNCT03420430 2024-09-25
Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care
Genelux Corporation
No longer available
NCT05219266 2024-06-28
Managed Access Programs for PKC412, Midostaurin
Novartis
No longer available
NCT05627466 2024-02-15
US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Gilead Sciences
No longer available
NCT04678466 2022-05-31
Flotetuzumab Expanded Access Program
MacroGenics
No longer available
NCT02624570 2020-07-15
AMLFLT3
Novartis
No longer available
NCT03723057 2019-10-24
Expanded Access for AG-221
Celgene
No longer available
NCT03114228 2019-10-15
An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)
Novartis
No longer available
NCT03409081 2018-09-13
Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Astellas Pharma Inc
No longer available